Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$51.81
À la fermeture: Sep 11 EDT
$52.13
0.320.62%
Pré-commercialisation: 9:03 AM EDT
Comments
Loading...
Évaluations des analystes, objectifs de prix, prévision
CRISPR Therapeutics AG a un objectif de cours consensus de $71, basé sur les évaluations des 26 analystes. Le plus élevé est de $120 attribué par Truist Securities le février 12, 2025, et le plus bas est de $30 attribué par TD Cowen le décembre 11, 2023. Les 3 dernières évaluations d'analystes ont été publiées par HC Wainwright & Co., Barclays et Chardan Capital le août 7, 2025, août 6, 2025 et août 5, 2025. Avec un objectif de cours moyen de $72.67 entre HC Wainwright & Co., Barclays et Chardan Capital, il y a une variation implicite de 39.40% upside pour CRISPR Therapeutics AG à partir de ces dernières évaluations d'analystes.
Sociétés d'analyse émettant des recommandations1
HC Wainwright & Co.
Barclays
Chardan Capital
RBC Capital
B of A Securities
1calculé à partir des notes des analystes
Notes d'analystes pour CRISPR Therapeutics
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
08/07/2025 | 53.46% | HC Wainwright & Co. | $65 → $80 | Maintains | Buy | |||
08/06/2025 | 7.42% | Barclays | $42 → $56 | Maintains | Equal-Weight | |||
08/05/2025 | 57.3% | Chardan Capital | $82 → $82 | Maintains | Buy | |||
08/05/2025 | -19.43% | RBC Capital | $38 → $42 | Maintains | Sector Perform | |||
07/22/2025 | 49.63% | B of A Securities | $79 → $78 | Maintains | Buy | |||
07/08/2025 | 55.38% | Needham | $81 → $81 | Reiterates | Buy → Buy | |||
06/27/2025 | -13.68% | Clear Street | → $45 | Downgrade | Buy → Hold | |||
06/27/2025 | 101.42% | Piper Sandler | $105 → $105 | Reiterates | Overweight → Overweight | |||
06/27/2025 | 64.97% | JMP Securities | $86 → $86 | Reiterates | Market Outperform → Market Outperform | |||
06/27/2025 | 24.69% | HC Wainwright & Co. | $65 → $65 | Reiterates | Buy → Buy | |||
06/26/2025 | 55.38% | Needham | $81 → $81 | Reiterates | Buy → Buy | |||
06/26/2025 | 57.3% | Chardan Capital | $82 → $82 | Maintains | Buy | |||
05/21/2025 | 64.97% | JMP Securities | $86 → $86 | Reiterates | Market Outperform → Market Outperform | |||
05/20/2025 | 55.38% | Needham | $81 → $81 | Reiterates | Buy → Buy | |||
05/20/2025 | 24.69% | HC Wainwright & Co. | $65 → $65 | Reiterates | Buy → Buy | |||
05/09/2025 | -19.43% | Barclays | $56 → $42 | Maintains | Equal-Weight | |||
05/08/2025 | -9.84% | Goldman Sachs | $53 → $47 | Maintains | Neutral | |||
05/07/2025 | 55.38% | Needham | $84 → $81 | Maintains | Buy | |||
05/07/2025 | 57.3% | Chardan Capital | $84 → $82 | Maintains | Buy | |||
04/09/2025 | 61.14% | Needham | $84 → $84 | Reiterates | Buy → Buy | |||
02/19/2025 | — | Cantor Fitzgerald | — | Reiterates | Neutral → Neutral | |||
02/18/2025 | 57.3% | Citigroup | $89 → $82 | Maintains | Buy | |||
02/14/2025 | -38.62% | Morgan Stanley | $30 → $32 | Maintains | Underweight | |||
02/14/2025 | 89.91% | Evercore ISI Group | $60 → $99 | Upgrade | In-Line → Outperform | |||
02/13/2025 | 9.34% | Goldman Sachs | $66 → $57 | Maintains | Neutral | |||
02/13/2025 | 64.97% | JMP Securities | $86 → $86 | Reiterates | Market Outperform → Market Outperform | |||
02/13/2025 | -6% | Stifel | $53 → $49 | Maintains | Hold | |||
02/13/2025 | 24.69% | HC Wainwright & Co. | $65 → $65 | Reiterates | Buy → Buy | |||
02/13/2025 | 61.14% | Chardan Capital | $94 → $84 | Maintains | Buy | |||
02/12/2025 | 130.19% | Truist Securities | $100 → $120 | Maintains | Buy | |||
02/12/2025 | -7.92% | RBC Capital | $53 → $48 | Maintains | Sector Perform | |||
02/12/2025 | 61.14% | Needham | $84 → $84 | Reiterates | Buy → Buy | |||
02/12/2025 | 7.42% | Barclays | $55 → $56 | Maintains | Equal-Weight | |||
02/03/2025 | 24.69% | HC Wainwright & Co. | → $65 | Initiates | → Buy | |||
01/14/2025 | 61.14% | Needham | $84 → $84 | Reiterates | Buy → Buy | |||
01/07/2025 | 63.05% | B of A Securities | $98 → $85 | Maintains | Buy | |||
12/20/2024 | 64.97% | JMP Securities | $86 → $86 | Reiterates | Market Outperform → Market Outperform | |||
12/10/2024 | 80.32% | Chardan Capital | $94 → $94 | Maintains | Buy | |||
11/06/2024 | 1.67% | RBC Capital | $53 → $53 | Reiterates | Sector Perform → Sector Perform | |||
11/06/2024 | 5.51% | Barclays | $59 → $55 | Maintains | Equal-Weight | |||
11/06/2024 | 61.14% | Needham | $84 → $84 | Reiterates | Buy → Buy | |||
10/04/2024 | 1.67% | RBC Capital | $60 → $53 | Maintains | Sector Perform | |||
08/12/2024 | 91.83% | Truist Securities | $120 → $100 | Maintains | Buy | |||
08/08/2024 | — | Cantor Fitzgerald | — | Reiterates | → Neutral | |||
08/06/2024 | 13.18% | Stifel | $60 → $59 | Maintains | Hold | |||
08/06/2024 | 13.18% | Barclays | $67 → $59 | Maintains | Equal-Weight | |||
08/06/2024 | 15.1% | RBC Capital | $66 → $60 | Maintains | Sector Perform | |||
08/06/2024 | 80.32% | Chardan Capital | $112 → $94 | Maintains | Buy | |||
08/06/2024 | 61.14% | Needham | $88 → $84 | Maintains | Buy | |||
06/28/2024 | — | Guggenheim | — | Assumes | → Neutral | |||
06/27/2024 | 68.81% | Needham | $88 → $88 | Reiterates | Buy → Buy | |||
06/17/2024 | 101.42% | Piper Sandler | $105 → $105 | Reiterates | Overweight → Overweight | |||
06/17/2024 | 68.81% | Needham | $88 → $88 | Reiterates | Buy → Buy | |||
05/23/2024 | 61.14% | Citigroup | $89 → $84 | Maintains | Buy | |||
05/10/2024 | 82.24% | Oppenheimer | $102 → $95 | Maintains | Outperform | |||
05/09/2024 | 64.97% | JMP Securities | $86 → $86 | Reiterates | Market Outperform → Market Outperform | |||
05/09/2024 | 24.69% | Wells Fargo | $70 → $65 | Maintains | Equal-Weight | |||
05/09/2024 | — | Cantor Fitzgerald | — | Reiterates | → Neutral | |||
05/09/2024 | 28.52% | Barclays | $80 → $67 | Maintains | Equal-Weight | |||
05/09/2024 | 68.81% | Needham | $90 → $88 | Maintains | Buy | |||
05/09/2024 | -0.25% | Baird | $46 → $52 | Maintains | Neutral | |||
04/18/2024 | 70.73% | Citigroup | $88 → $89 | Maintains | Buy | |||
04/11/2024 | 72.65% | Needham | $90 → $90 | Reiterates | Buy → Buy | |||
03/06/2024 | 89.91% | Mizuho | $82 → $99 | Maintains | Buy | |||
02/26/2024 | -7.92% | Morgan Stanley | $46 → $48 | Maintains | Underweight | |||
02/22/2024 | 26.61% | RBC Capital | $57 → $66 | Maintains | Sector Perform | |||
02/22/2024 | 34.28% | Wells Fargo | $55 → $70 | Maintains | Equal-Weight | |||
02/22/2024 | 53.46% | Barclays | $61 → $80 | Maintains | Equal-Weight | |||
02/22/2024 | 114.85% | Chardan Capital | $110 → $112 | Maintains | Buy | |||
02/21/2024 | 72.65% | Needham | $88 → $90 | Maintains | Buy | |||
02/15/2024 | — | Wolfe Research | — | Initiates | → Peer Perform | |||
12/11/2023 | 9.34% | RBC Capital | $50 → $57 | Maintains | Sector Perform | |||
12/11/2023 | 206.92% | Truist Securities | $220 → $160 | Maintains | Buy | |||
12/11/2023 | 17.02% | Barclays | $56 → $61 | Maintains | Equal-Weight | |||
12/11/2023 | -42.45% | TD Cowen | → $30 | Downgrade | Market Perform → Underperform | |||
12/11/2023 | 53.46% | JMP Securities | $74 → $80 | Maintains | Market Outperform | |||
12/11/2023 | 68.81% | Needham | $85 → $88 | Maintains | Buy | |||
12/08/2023 | 322.02% | Truist Securities | → $220 | Reiterates | Buy → Buy | |||
12/08/2023 | 57.3% | Mizuho | → $82 | Reiterates | Buy → Buy | |||
12/05/2023 | 41.95% | JMP Securities | → $74 | Reiterates | Market Outperform → Market Outperform | |||
11/13/2023 | -19.43% | Morgan Stanley | $43 → $42 | Maintains | Underweight | |||
11/07/2023 | -4.09% | RBC Capital | $55 → $50 | Maintains | Sector Perform | |||
11/07/2023 | 63.05% | Needham | $88 → $85 | Maintains | Buy | |||
11/01/2023 | 68.81% | Needham | → $88 | Reiterates | Buy → Buy | |||
10/30/2023 | 68.81% | Needham | → $88 | Reiterates | Buy → Buy | |||
10/17/2023 | — | Cantor Fitzgerald | — | Downgrade | Overweight → Neutral | |||
09/27/2023 | 57.3% | Mizuho | → $82 | Initiates | → Buy | |||
08/18/2023 | 34.28% | Citigroup | → $70 | Upgrade | Neutral → Buy | |||
08/17/2023 | 34.28% | Citigroup | → $70 | Upgrade | Neutral → Buy | |||
08/14/2023 | -17.51% | Morgan Stanley | $42 → $43 | Maintains | Underweight | |||
08/10/2023 | 95.66% | Oppenheimer | → $102 | Reiterates | Outperform → Outperform | |||
08/08/2023 | 20.85% | Credit Suisse | $62 → $63 | Maintains | Neutral | |||
08/08/2023 | 43.87% | EF Hutton | → $75 | Reiterates | Buy → Buy | |||
08/08/2023 | 68.81% | Needham | → $88 | Reiterates | Buy → Buy | |||
08/08/2023 | 111.01% | Chardan Capital | $123 → $110 | Maintains | Buy | |||
07/25/2023 | 41.95% | JMP Securities | → $74 | Reiterates | Market Outperform → Market Outperform | |||
06/09/2023 | 68.81% | Needham | $82 → $88 | Reiterates | Buy → Buy | |||
06/09/2023 | 41.95% | JMP Securities | $70 → $74 | Maintains | Market Outperform | |||
06/09/2023 | 43.87% | EF Hutton | → $75 | Reiterates | → Buy | |||
06/01/2023 | 22.77% | Barclays | $61 → $64 | Maintains | Equal-Weight |
FAQ
Quel est le cours indicatif de l'action CRISPR Therapeutics (CRSP) ?
Le dernier objectif de prix pour CRISPR Therapeutics (NASDAQ:CRSP) a été rapporté par HC Wainwright & Co. le août 7, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $80.00 s'attendant à ce que CRSP se rise dans les 12 prochains mois (un possible changement de 53.46% upside). 42 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
Quelle est la note d'analyste la plus récente pour CRISPR Therapeutics (CRSP) ?
La dernière note d'analyste pour CRISPR Therapeutics (NASDAQ:CRSP) a été fournie par HC Wainwright & Co., et CRISPR Therapeutics maintenu leur note buy.
Quand a eu lieu la dernière mise à niveau pour CRISPR Therapeutics (CRSP) ?
La dernière amélioration pour CRISPR Therapeutics AG a eu lieu le février 14, 2025 lorsque Evercore ISI Group a augmenté leur objectif de prix à $99. Evercore ISI Group avait précédemment an in-line pour CRISPR Therapeutics AG.
Quand a eu lieu la dernière dégradation pour CRISPR Therapeutics (CRSP) ?
La dernière réduction pour CRISPR Therapeutics AG a eu lieu le juin 27, 2025 lorsque Clear Street a changé leur objectif de prix de N/A à $45 pour CRISPR Therapeutics AG.
Quand la prochaine note d'analyste sera-t-elle publiée ou mise à jour pour CRISPR Therapeutics (CRSP) ?
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de CRISPR Therapeutics, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour CRISPR Therapeutics a été déposée le août 7, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers août 7, 2026.
La note d'analyste pour CRISPR Therapeutics (CRSP) est-elle correcte ?
Bien que les évaluations soient subjectives et changeront, la dernière note de CRISPR Therapeutics (CRSP) était un maintenu avec un objectif de prix de $65.00 à $80.00. Le prix actuel de CRISPR Therapeutics (CRSP) est de $52.13, ce qui est out of la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.